Skin News

Thursday, February 19, 2009 Raptiva^® Pulled in EU After 3rd PML Case; FDA Warns US Docs
European regulators suspended sales of the psoriasis drug Raptiva^® after a 3rd PML death, and the FDA warned US doctors of a 4th suspected case...

Wednesday, February 18, 2009 Ustekinumab Reduces Psoriatic Arthritis Pain, Clears Lesions
Ustekinumab (CNTO 1275), a new monoclonal antibody that blocks interleukin (IL)-12 and IL-23 (IL-23), may help thwart the pain, swelling and lesions of psoriatic arthritis...

Friday, February 06, 2009 Galderma's Vectical™ Gets FDA OK for Psoriasis
Vectical vitamin D3 ointment has been approved by the FDA for mild-to-moderate plaque psoriasis...

Friday, January 30, 2009 Psoriasis Gene Studies Fill In More Pieces of the Puzzle
New genetics data suggest novel approaches to psoriasis treatment...

Wednesday, January 28, 2009 Half of Psoriasis Patients Improve With Online Support Groups
Nearly half of psoriasis patients said their health status and disease severity improved after they joined an online psoriasis support group...

Monday, January 26, 2009 4 Factors in Lupus Noncompliance
Lupus patients cite specific reasons for taking (or not taking) their meds. Changes in physician-patient communications might fix some of these problems...

Monday, December 08, 2008 Say Goodbye to Plantar Fasciitis After 15-Minute Treatment
Combining an ultrasound-guided dry needling technique with steroid injection is 95% effective at relieving plantar fasciitis within 3 weeks...

Friday, December 05, 2008 SSc Risk 60-Fold Higher in Raynaud's with SSc Antibodies, NCM Changes
Microvascular damage and systemic sclerosis (SSc)-specific antibodies can predict which Raynaud's phenomenon patients will progress to systemic sclerosis, and when...

Monday, November 24, 2008 Scleroderma Stem Cell Transplants Advance, Phase III Studies Recruiting Patients
Pilot data on systemic sclerosis (SSc) patients treated with autologous stem cell transplants suggest durable improvements in skin thickening and lung function. Phase III randomized trials are still open to enrollment...

Tuesday, November 18, 2008 Centocor's Golimumab Gives Durable Skin, Joint Relief in Psoriatic Arthritis, ACR Studies Say
More than half of active psoriatic arthritis patients receiving subcutaneous injections of 50 mg or 100 mg of golimumab (CNTO 148) every 4 weeks showed improvements that lasted through 1 year in the joint and skin symptoms...